arrow
M

Mònica Sánchez-Guixé

THE BARCELONA INSTITUTE OF SCIENCE AND TECHNOLOGY
H指数:8
被引数:389

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity

神经母细胞瘤患者中BAX的缺失揭示了延迟性凋亡但保持了化疗敏感性

2026-07-020
OA
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

下一代口服选择性雌激素受体降解剂Camizestrant (AZD9833) 抑制ER乳腺癌生长并克服内分泌和CDK4/6抑制剂抗性

2023-09-1916
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (September, 10.1038/s41467-022-32828-6, 2022)

高p16表达和杂合RB1丢失是ER乳腺癌中CDK4/6抑制剂抗性的生物标志物 (9月,10.1038/s41467-022-32828-6,2022)

2022-11-140
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

高p16表达和杂合RB1缺失是ER乳腺癌中CDK4/6抑制剂耐药的生物标志物

2022-09-0747
OAAI
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2022-01-0515
OA
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

PI3K激活促进HER2-negative乳腺癌对eribulin的耐药性

2021-03-1513
OAAI
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
2020-07-1527
OAAI
STUB1 mutations in autosomal recessive ataxias - evidence for mutation-specific clinical heterogeneity

常染色体隐性共济失调中的STUB1突变-突变特异性临床异质性的证据

2014-09-2665
OAAI